125I-Iododeoxyuridine for the treatment of a brain tumor model: Selection of conditions for optimal effectiveness

Open Nuclear Medicine Journal

Volumn 3, Issue , 2011, Pages 19-24

  Lehnert, Shirley ^a   Li, Yongbiao ^a   Bump, Ed ^b   Riddoch, Bill ^b   Chenite, Abdellatif ^c   Shive, Matthew ^c  

^a MCGILL UNIVERSITY   (Canada)

^b Draximage   (Canada)

^c Biosyntech Inc   (Canada)

Author keywords

125IUdR; Glioblastoma; Intratumoral drug delivery; Thermosensitive hydrogel

Indexed keywords

CHITOSAN; IDOXURIDINE I 125; METHOTREXATE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; GLIOBLASTOMA; HYDROGEL; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; SLOW RELEASE FORMULATION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80055116288     PISSN: None     EISSN: 1876388X     Source Type: Journal    
DOI: 10.2174/1876388X01103010019     Document Type: Article

References (41)

1. Khasraw M, Lassman A. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010; 12: 26-33.
2. Jenkinson M, Plessis DD, Walker C, Smith T. Advanced MRI in the management of adult gliomas. Br J Neurosurg 2007; 21(6): 550-61.
3. Kreth F, Thon N, Siefert A, Tonn J. The place of interstitial brachytherapy and radiosurgery for low-grade gliomas. Adv Tech Stand Neurosurg 2010; 35: 183-212.
4. Chang C, Chen W, Wei K, et al. High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes. J Neurooncol 2003; 61(1): 45-55.
5. Chow K, Gottschalk S. Cellular immunotherapy for high-grade glioma. Immunotherapy 2011; 3(3): 423-34.
6. Sköld K, Gorlia T, Pellettieri L, Giusti V, H-Stenstam B, Hopewell J. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Br J Radiol 2010; 83: 596-603.
7. Kanu O, Mehta A, Di C, et al. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 2009; 13: 701-18.
8. Candolfi M, Xiong W, Yagiz K, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci USA 2010; 107: 20021-6.
9. Leong K, Brott B, Langer R. Bioerodible polyanhydrides as drug carrier matrices. I: characterization, degradation and release characteristics. J Biomed Mater Res 1985; 19: 941-55.
10. Leong K, D'Amore P, Marletta M, Langer R. Bioerodible polyanhydrides as drug-carrier matrices. II Biocompatibility and chemical reactivity. Biomed Mater Res 1986; 20: 51-64.
11. Sipos E, Tyler B, Piantadosi S, Burger P, Brem H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 1997; 39: 383-9.
12. LaVan D, Lynn D, Langer R. Moving smaller in drug discovery and delivery. Nat Rev Drug Discov 2002; 1:77-84.
13. Jain R. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21: 2475-90.
14. Chenite A, Buschmann M, Wang D, Chaput C, Kandani N. Rheological characterization of thermogelling chitosan/glycerolphosphate solutions. Carbohydr Polym 2001; 46: 39-47.
15. Jarry C, Chaput C, Chenite A, Renaud M, Buschmann M, Leroux J. Effects of steam sterilization on thermogelling chitosan-based gels. J Biomed Mater Res 2001; 58: 127-35.
16. Chenite A, Chaput C, Wang D, et al. Novel injectable neutral solutions. Biomaterials 2000; 78: 187-97.
17. Charlton D, Booz J. A Monte Carlo treatment of the decay of 125I. Radiat Res l981; 87: 10-23.
18. Kassis A, Sastry K, Adelstein S. Kinetics of uptake retention and radiotoxicity of 125IUdR in mammalian cells, implications of localized energy deposition by Auger processes. Radiat Res 1987; 109: 78-99.
19. Hofer K, Harris C, Smith J. Radiotoxicity of intracellular Ga, 125I and 'H. Nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia. Int J Radiat Biol 1975; 28: 225-41.
20. Kassis A, Howell R, Sastry K, Adelstein S. Positional effects of Auger decays in mammalian cells in culture. In: Baverstock K, Charlton D, Eds. DNA damage by Auger emitters. London: Taylor and Francis; 1988; pp. 1-13.
21. Kassis A, Fayad F, Kinsey B, Sastry K, Adelstein S. Radiotoxicity of an 'l-labeled DNA intercalator in mammalian cells. Radiat Res 1989; 18: 283-94.
22. Eidinoff M, Cheong L, Gurpide EG, Benua R, Ellison R. Incorporation of 5-iodo-uracil labelled with iodine-131 into the deoxyribonucleic acid of human leukaemic leucocytes following in vivo administration of 5- iododeoxyuridine labelled with iodine-131. Nature 1959; 183: 1686-7.
23. Kassis, A, Fayad F, Kinsey B, Sastry K, Taube R, Adelstein S. Radiotoxicity of 125I in mammalian cells. Radiat Res 1987; 111: 305-18.
24. Garrett C, Wataya Y, Santi D. Thymidylate synthetase. Catalysis of dehalogenation of 5-bromo- and 5-iodo-2'-deoxyuridylate. Biochemistry 1979; 18: 2798-804.
25. Calabresi P, Cardoso S, Finch S, et al. Initial clinical studies with 5- iodo-2'- deoxyuridine. Cancer Res 1961; 21: 550-9.
26. Prusoff W. A review of some aspects of 5-iododeoxyuridine and azauridine. Cancer Res 1963; 23: 1246-59.
27. Lee D, Prensky W, Krause G, Hughes W. Blood thymidine level and iododeoxyuridine incorporation and reutilization in DNA in mice given long-acting thymidine pellets. Cancer Res 1976; 36: 4577-83.
28. Klecker R, Jenkins J, Kinsella T, Fine R, Strong J, Collins J. Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation. Pharmacol Ther 1985; 38: 45-51.
29. Bloomer W, Adelstein S. 5-125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature 1977; 265: 620-1.
30. Baranowska-Kortylewicz J, Makrigiorgos G, van den Abbeele A, Berman R, Adelstein S, Kassis A. 5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radial Oncol Biol Phys 1991; 21: 1541-51.
31. Kassis A, Wen P, van den Abeele A, et al. 5-[125I]iodo-2'- deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med 1998; 39: 1148-54.
32. Mester J, DeGoeij K, Sluyser M. Modulation of [5-125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors. Eur J Cancer 1996; 32A: 1603-8.
33. Macapinlac H, Kemeny N, Daghighian F, et al. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med 1996; 37: 25S-9S.
34. Benda P, Someda K, Messer J. Morphological and immunochemical studies of rat glial tumor and clonal strains propagated in tissue culture. J Neurosurg 1971; 34: 310-23.
35. San-Galli F, Vrignaud P, Robert J, Coindre J, Cohadon F. Assessment of the experimental model of transplanted C6 glioblastoma in Wistar rats. J Neurooncol 1989; 7: 299-304.
36. Li Y, Owusu A, Lehnert S. Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2004; 58: 519-27.
37. Kassis A, Makrigiorgos G, Adelstein S. Dosimetric considerations and therapeutic potential of Auger electron emitters. In: Adelstein S, Kassis A, Burt R, Eds. Frontiers in nuclear medicine: dosimetry of administered radionuclides, proceedings of a symposium, 1989. Washington, DC: American College of Nuclear Physicians 1990: pp. 257-74.
38. Kassis A. Dosimetric aspects of administered radionuclides. In: Carpi A, Sagripanti A, Mittermayer C, Eds. Progress in clinical oncology. Munich: Sympomed Medical Publishers 1992: pp. 112-24.
39. Sahu S, Wen P, Foulon C, et al. Intrathecal 5-[125I]Iodo-2'- Deoxyuridine in a Rat Model of Leptomeningeal Metastases. J Nucl Med 1997; 38: 386-90.
40. Kassis A, Dahman B, Adelstein S. In vivo therapy of neoplastic meningitis with methotrexate and 5-[125I]iodo-20-deoxyuridine. Acta Oncol 2000; 39: 731-7.
41. Araki T, Yamamoto A, Yamada M. Accurate determination of DNA content in single cell nuclei stained with Hoechst 33258 fluorochrome at high salt concentration. Histochemistry 1987; 87: 33l-8.